Vertex Pharmaceuticals Inc
VRTX447.380USD
-2.140-0.48%
Close 12/18, 16:00（ET）Quotes delayed by 15 min
113.61BMarket Cap
31.27P/E TTM
More Details of Vertex Pharmaceuticals Inc Company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc Info
Ticker SymbolVRTX
Company nameVertex Pharmaceuticals Inc
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Number of employees6100
Security typeOrdinary Share
Fiscal year-endJul 24
Address50 Northern Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16173416393
Websitehttps://www.vrtx.com/
Ticker SymbolVRTX
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Company Executives of Vertex Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.31K
-2.22%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
-11.24%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-5.51%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
By RegionUSD
Name
Revenue
Proportion
United States
1.83B
62.08%
Europe
910.90M
30.94%
Other
205.60M
6.98%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Other
63.49%
Shareholders
Shareholders
Proportion
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Other
63.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
60.06%
Investment Advisor/Hedge Fund
28.01%
Research Firm
2.35%
Pension Fund
2.27%
Bank and Trust
2.08%
Sovereign Wealth Fund
1.50%
Hedge Fund
1.14%
Individual Investor
0.14%
Insurance Company
0.09%
Other
2.36%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
2933
249.27M
98.24%
-2.14M
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
28.73M
11.21%
+198.84K
+0.70%
Jun 30, 2025
The Vanguard Group, Inc.
23.86M
9.31%
+479.23K
+2.05%
Jun 30, 2025
Capital Research Global Investors
16.11M
6.28%
+1.57M
+10.81%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
14.15M
5.52%
+156.31K
+1.12%
Jun 30, 2025
State Street Investment Management (US)
11.78M
4.59%
-13.43K
-0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.93M
2.31%
+166.99K
+2.90%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
5.26M
2.05%
-18.59K
-0.35%
Aug 31, 2025
Wellington Management Company, LLP
4.81M
1.88%
-641.36K
-11.76%
Jun 30, 2025
Capital International Investors
2.64M
1.03%
+1.99M
+305.59%
Jun 30, 2025
AllianceBernstein L.P.
4.38M
1.71%
+424.81K
+10.75%
Jun 30, 2025
View more
Related ETFs
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Name
Proportion
VanEck Biotech ETF
9.71%
ProShares Ultra Nasdaq Biotechnology
8.83%
Invesco Nasdaq Biotechnology ETF
8.76%
iShares Biotechnology ETF
7.43%
Invesco Biotechnology & Genome ETF
5.35%
Natixis Loomis Sayles Focused Growth ETF
4.48%
First Trust NASDAQ Pharmaceuticals ETF
4.23%
First Trust NYSE Arca Biotechnology Index Fund
3.5%
Franklin Genomic Advancements ETF
3.33%
Simplify Health Care ETF
3.25%
View more
VanEck Biotech ETF
Proportion9.71%
ProShares Ultra Nasdaq Biotechnology
Proportion8.83%
Invesco Nasdaq Biotechnology ETF
Proportion8.76%
iShares Biotechnology ETF
Proportion7.43%
Invesco Biotechnology & Genome ETF
Proportion5.35%
Natixis Loomis Sayles Focused Growth ETF
Proportion4.48%
First Trust NASDAQ Pharmaceuticals ETF
Proportion4.23%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.5%
Franklin Genomic Advancements ETF
Proportion3.33%
Simplify Health Care ETF
Proportion3.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vertex Pharmaceuticals Inc?
The top five shareholders of Vertex Pharmaceuticals Inc are:
Capital World Investors holds 28.73M shares, accounting for 11.21% of the total shares.
The Vanguard Group, Inc. holds 23.86M shares, accounting for 9.31% of the total shares.
Capital Research Global Investors holds 16.11M shares, accounting for 6.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 14.15M shares, accounting for 5.52% of the total shares.
State Street Investment Management (US) holds 11.78M shares, accounting for 4.59% of the total shares.
Capital World Investors holds 28.73M shares, accounting for 11.21% of the total shares.
The Vanguard Group, Inc. holds 23.86M shares, accounting for 9.31% of the total shares.
Capital Research Global Investors holds 16.11M shares, accounting for 6.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 14.15M shares, accounting for 5.52% of the total shares.
State Street Investment Management (US) holds 11.78M shares, accounting for 4.59% of the total shares.
What are the top three shareholder types of Vertex Pharmaceuticals Inc?
The top three shareholder types of Vertex Pharmaceuticals Inc are:
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
How many institutions hold shares of Vertex Pharmaceuticals Inc (VRTX)?
As of 2025Q3, 2933 institutions hold shares of Vertex Pharmaceuticals Inc, with a combined market value of approximately 249.27M, accounting for 98.24% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.32%.
What is the biggest source of revenue for Vertex Pharmaceuticals Inc?
In FY2025Q2, the TRIKAFTA business generated the highest revenue for Vertex Pharmaceuticals Inc, amounting to 2.55B and accounting for 86.65% of total revenue.
